Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Tuesday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Tuesday, February 25th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Cytosorbents has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

CTSO stock opened at $1.10 on Tuesday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The business’s fifty day simple moving average is $1.07 and its two-hundred day simple moving average is $1.05. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The firm has a market cap of $60.15 million, a price-to-earnings ratio of -3.06 and a beta of 0.78.

Hedge Funds Weigh In On Cytosorbents

Institutional investors have recently made changes to their positions in the company. Millennium Management LLC purchased a new position in shares of Cytosorbents during the fourth quarter valued at $30,000. Renaissance Technologies LLC increased its stake in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares during the period. Northern Trust Corp increased its stake in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Cytosorbents during the fourth quarter valued at $99,000. Finally, Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.